课题基金 / 基金详情

Development of recombinant rsolCD39-PSGL as a novel therapeutic with anti-thrombotic and anti-inflammatory effects

Development of recombinant rsolCD39-PSGL as a novel therapeutic with anti-thrombotic and anti-inflammatory effects
重组rsolCD39-PSGL作为具有抗血栓和抗炎作用的新型治疗剂的开发
批准号:
nhmrc : 520697
负责人:
Prof Anthony D'Apice
金额:
$12.43万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Development Grants
财政年份:
2008
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2008-01-01 至 2009-12-31

项目摘要

项目成果

Prof Anthony D'Apice的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Heart disease and stroke are due to a narrowing of arteries followed by occlusion, due a combination of clot formation initiated by platelet clumping, and inflammation surrounding the vessel wall. The currently available drugs are often limited by the adverse reaction of bleeding. We will investigate the efficiency of a new drug to prevent clot formation and inflammation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CD39 protects against renal ischaemic-reperfusion injury
  • 批准号:
    nhmrc : 447706
  • 项目类别:
    NHMRC Project Grants
  • 资助金额:
    $29.44万
  • 财政年份:
    2007
  • 负责人:
    Prof Anthony D'Apice
  • 依托单位:
A novel CD39-like ecto-NTPDase of Legionella pneumophila
  • 批准号:
    nhmrc : 436607
  • 项目类别:
    NHMRC Project Grants
  • 资助金额:
    $24.14万
  • 财政年份:
    2007
  • 负责人:
    Prof Anthony D'Apice
  • 依托单位:
Antithrombotic effect of NTPDase1/CD39
  • 批准号:
    nhmrc : 344801
  • 项目类别:
    NHMRC Project Grants
  • 资助金额:
    $24.62万
  • 财政年份:
    2005
  • 负责人:
    Prof Anthony D'Apice
  • 依托单位:
Immune responses to the alpha-Gal xenoantigen
  • 批准号:
    nhmrc : 204700
  • 项目类别:
    NHMRC Project Grants
  • 资助金额:
    $18.07万
  • 财政年份:
    2002
  • 负责人:
    Prof Anthony D'Apice
  • 依托单位:
海外基金